Navigation Links
Progress toward new chemotherapy agents
Date:3/26/2012

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

Merino will discuss his efforts toward designing these new anticancer agents Tuesday, March 27, at The Chemistry of Life: Spring National Meeting and Exposition of the American Chemical Society in San Diego.

At that meeting, Merino will show a new anticancer agent that targets cancerous cells by zeroing-in on the "pollutants" produced by the characteristic metabolism within tumors. This agent, which Merino calls a "ROS-caged agent," is activated by oxidative stress, a signature of cancerous activity.

"Cancerous cells use energy differently from other cells," Merino said. "Like an automobile engine with the gas pedal pushed to the floor, they give off a unique sort of pollution because they are not as efficient in using energy. Cancer cells don't use metabolism all the way through. We have found key enzymes that contribute to this characteristic signature."

This signature results from the build-up of reactive oxygen species, known as ROS. This environment creates a chemical target that Merino and his team can target with chemical systems. Merino describes his findings as a preliminary description of the factors that can make drug delivery much more selective.

"We are looking for chemicals that operate like heat-seeking missiles that attack only cancerous cells," Merino said. "If we are successful, we can create drugs with far fewer side effects."

The side effects associated with chemotherapy hair loss and weight loss are generated from the mechanism used to target today's family of drugs. Because cancerous cells reproduce rapidly, chemotherapy targets rapidly reproducing cells. The problem, Merino said, is that cells in the stomach lining and cells in our hair follicles also reproduce rapidly so conventional chemotherapy kills those cells, too.

A better understanding of cancer metabolism is an essential part of the work, but so is the basic chemistry involved in creating targeted compounds.

"We are continually making new compounds," Merino said, "but very few of them give any indication of working. Out of hundreds of candidates, we have one moving into a mouse model, and another that looks promising."


'/>"/>

Contact: Greg Hand
greg.hand@uc.edu
513-556-1822
University of Cincinnati
Source:Eurekalert  

Related medicine news :

1. American Red Cross Issues One-Month Progress Report for Haiti Earthquake
2. Herpes Drug Might Also Slow HIV Progression
3. Study Reports Progress Against Fatal Brain Cancer
4. Delcath Systems to Conduct Conference Call to Update Investors on Recent Progress
5. HIV and noncommunicable diseases hinder the progress of poor countries Millennium Development Goals
6. Congressional Testimony: Progress Made But Much More to Do for Americas Veterans
7. Fifty years of the light fantastic: Laser advances spark scientific progress
8. Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts
9. Progress Made Against Tough-to-Treat Biliary Tract Cancers
10. Targeting the blood-brain barrier may delay progression of Alzheimers disease
11. Statins may slow progression of multiple sclerosis, new study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progress toward new chemotherapy agents
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health ... Distinction, recognizing the organization as a top behavioral service provider in the country. ... clinical quality, staff satisfaction and qualifications, and consumer satisfaction. These areas are measured ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has ... knowledge resources, including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, ... more than 9,000 documents, webinars and videos available online, visit the METTLER ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... ... the availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit ... EHS audit protocols to understand the scope of their EHS regulatory obligations and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, ... Commercialization of Public Research (the Florida Institute) ... agreement SegAna, LLC, an Orlando ... Central Florida. The Florida Institute supports new company ... funding gaps for companies spinning out of Florida-based universities ...
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ Cartilage ... Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - Forecast ... USD 779.8 Million by 2021 from USD 414.6 Million in 2016, ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: